Video

Pharmacist Medication Insights: Dupilumab for Atopic Dermatitis

Dupilumab (Dupixent) was approved in 2017 for the treatment of adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies.

Dupilumab (Dupixent, Sanofi-Regeneron) is approved for the treatment of atopic dermatitis (AD) and corticosteroid-dependent or eosinophilic asthma in patients aged 12 years or older. The drug is a monoclonal antibody touted for its mechanism of blocking interleukin (IL) pathways integral to various inflammatory diseases.

Dupilumab is administered by subcutaneous injection with a 300 mg pre-filled syringe for patients with CRSwNP every other week at different injection sites. It is also approved for indications in moderate-to-severe asthma and moderate-to-severe AD.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Phone call, pharmacist woman and writing on medicine checklist, customer service or virtual pharmacy support. Serious doctor with medical notes, health insurance documents and talking at help desk
© 2025 MJH Life Sciences

All rights reserved.